Madrigal pharmaceuticals completes enrollment of clinical outcomes study of resmetirom in patients with compensated nash/mash cirrhosis

Conshohocken, pa., oct. 21, 2024 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (nash)/metabolic dysfunction-associated steatohepatitis (mash), today announced the maestro-nash outcomes trial evaluating resmetirom for the treatment of patients with compensated nash cirrhosis has completed enrollment.
MDGL Ratings Summary
MDGL Quant Ranking